NCM · Financial Statements

Alzamend Neuro, Inc. (ALZN) Revenue, Earnings & Financial Statements

$1.13 NCM: ALZN Market Cap $5.45M

Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Alzamend Neuro, Inc. most recently reported annual revenue of $0, a net loss of $9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Alzamend Neuro, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $9.0M.

Income Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Revenue$0$0$0$0$0$0$0$0$0$0
Operating Expenses$2.0M$1.0M$5.0M$4.0M$5.0M$12.0M$15.0M$10.0M$4.0M$9.0M
Operating Profit−$2.0M−$1.0M−$5.0M−$4.0M−$5.0M−$12.0M−$15.0M−$10.0M−$4.0M−$9.0M
Other Income$0$0$0$0$0$0$0$0$0$0
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$2.0M$1.0M$0$0$0$0$0$0$0$0
Profit Before Tax−$2.0M−$1.0M−$5.0M−$4.0M−$5.0M−$12.0M−$15.0M−$10.0M−$5.0M−$9.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$2.0M−$1.0M−$5.0M−$4.0M−$5.0M−$12.0M−$15.0M−$10.0M−$5.0M−$9.0M
EPS−$73.59−$27.71−$111.56−$83.56−$93.78−$187.31−$205.97−$132.33−$11.32−$2.63

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$3.0M$3.0M$1.0M$1.0M$1.0M$1.0M$1.0M$3.0M$1.0M$2.0M$3.0M$3.0M
Operating Profit−$3.0M−$3.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$3.0M−$1.0M−$2.0M−$3.0M−$3.0M
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$3.0M−$3.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$3.0M−$1.0M−$2.0M−$3.0M−$3.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$3.0M−$3.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$3.0M−$1.0M−$2.0M−$3.0M−$3.0M
EPS−$39.85−$33.97−$11.14−$11.42−$3.61−$1.70−$2.43−$1.28−$0.30−$0.58−$0.74−$0.68

Over the 10 years reported for Alzamend Neuro, Inc., borrowings decreased from $1.0M in 2017 to $0 in 2026, cash stood at $1.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.00 times.

Balance Sheet — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Total Assets$0$2.0M$2.0M$2.0M$3.0M$15.0M$6.0M$1.0M$5.0M$2.0M
Current Assets$0$2.0M$2.0M$2.0M$3.0M$14.0M$6.0M$0$4.0M$2.0M
Cash$0$1.0M$0$0$2.0M$14.0M$5.0M$0$4.0M$1.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$0
Fixed Assets$0$0$0$0$0$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$1.0M$0$1.0M$1.0M$1.0M$1.0M$3.0M$3.0M$1.0M$1.0M
Current Liabilities$1.0M$0$1.0M$1.0M$1.0M$1.0M$3.0M$3.0M$1.0M$1.0M
Borrowings$1.0M$0$0$0$0$0$0$0$0$0
Other Liabilities$0$0$1.0M$1.0M$1.0M$1.0M$3.0M$3.0M$1.0M$1.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves−$1.0M$2.0M$0$1.0M$2.0M$13.0M$3.0M−$3.0M$4.0M$1.0M

For Alzamend Neuro, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $8.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Operating Cash Flow−$1.0M−$2.0M−$1.0M−$2.0M−$3.0M−$7.0M−$9.0M−$8.0M−$7.0M−$8.0M
Investing Cash Flow$0$0$0$0$0$0$0$0−$1.0M$0
Financing Cash Flow$1.0M$0$0$2.0M$2.0M$0$0$0$0$0
Net Cash Flow$0$1.0M−$1.0M$0$2.0M$12.0M−$9.0M−$5.0M$4.0M−$3.0M
Free Cash Flow−$1.0M−$2.0M−$1.0M−$2.0M−$3.0M−$7.0M−$9.0M−$8.0M−$7.0M−$8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.06
FCF Yield-97.13%
Quick Ratio3.01
Interest Coverage818.59
Return 1Y-46.78%
Return 3Y-99.02%
Return 5Y-99.96%

Alzamend Neuro, Inc. (ALZN) financials — frequently asked questions

What is Alzamend Neuro, Inc.'s annual revenue?

Alzamend Neuro, Inc. (ALZN) reported annual revenue of $0 in its most recent fiscal year.

What is Alzamend Neuro, Inc.'s net profit?

Alzamend Neuro, Inc. (ALZN) reported a net loss of $9.0M in its most recent fiscal year.

What is ALZN EV/EBITDA?

Alzamend Neuro, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.06.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
ALZN Overview ALZN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.